Skip to main content
Zachary Goodman, MD, Pathology, Falls Church, VA, Inova Mount Vernon Hospital

ZacharyDaleGoodmanMD

Pathology Falls Church, VA

Anatomic Pathology, Clinical Pathology

Physician

Dr. Goodman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Goodman's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Pathology-Anatomic and Clinical, 1975 - 1980
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 1975

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1979 - 2024
  • VA State Medical License
    VA State Medical License 2010 - 2024
  • DC State Medical License
    DC State Medical License 2010 - 2013
  • FL State Medical License
    FL State Medical License 2010 - 2012
  • PA State Medical License
    PA State Medical License 2010 - 2010
  • American Board of Pathology Anatomic Pathology

Publications & Presentations

PubMed

Journal Articles

  • An Exploratory Study Examining How Nano-Liquid Chromatography–Mass Spectrometry and Phosphoproteomics Can Differentiate Patients with Advanced Fibrosis and Higher Perc...  
    Zobair M Younossi, Zachary D Goodman, BioMed Central

Press Mentions

  • Major Histocompatibility Complex Class I‐Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease
    Major Histocompatibility Complex Class I‐Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver DiseaseSeptember 30th, 2020
  • The Origins of the Modern‐Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman
    The Origins of the Modern‐Day Study of Drug Hepatotoxicity: Focus on Hyman J. ZimmermanMarch 2nd, 2020
  • New Long-Term Data Presented at AASLD Show Reduction in Liver Fibrosis and Cirrhosis in a Cohort of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (Sebelipase Alfa)
    New Long-Term Data Presented at AASLD Show Reduction in Liver Fibrosis and Cirrhosis in a Cohort of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (Sebelipase Alfa)November 11th, 2016

Hospital Affiliations